33 Leukemia Clinical Trials in Palo Alto, CA (2026)

Q: How do I join a clinical trial in Palo Alto?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you.

Recruiting Leukemia Studies in Palo Alto

NCT03539705Recruiting

Food Allergy Registry at a Single Site

This is a registry of participants who are interested in being screened for clinical trials at a single site....

Palo Alto, CA6,000 participantsStanford University

View Study Details

NCT04828603Recruiting

Understanding Allergies and Sensitizations in Healthy and Allergic Individuals

The purpose of this study is to strengthen our ability to accurately diagnose allergies and understand cellular, humoral, genetic components and physiological changes in allergic disease...

Palo Alto, CA2,500 participantsStanford University

View Study Details

NCT03539692Recruiting

Prescreening Protocol to Enroll in Food Allergy Clinical Studies at a Single Site

This is a protocol for prescreening of participants who would like to be in clinical studies in our Center at Stanford....

Palo Alto, CA1,000 participantsStanford University

View Study Details

NCT05254743Recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

The purpose of Part 1 of this study is to compare the efficacy and safety of pirtobruitinib (LOXO-305) to ibrutinib in participants with CLL/SLL; participants may or may not have already had treatment...

Palo Alto, CAPHASE3737 participantsLoxo Oncology, Inc.

View Study Details

NCT06943872Recruiting

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia...

Palo Alto, CAPHASE3630 participantsBeiGene

View Study Details

NCT04988555Recruiting

A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation

A phase 1/2 dose escalation / dose expansion study of Enzomenib (DSP-5336) in adult patients with acute leukemia....

Palo Alto, CAPHASE1606 participantsSumitomo Pharma America, Inc.

View Study Details

NCT06615050Recruiting

A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

The purpose of this study is to assess Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning ...

Palo Alto, CAPHASE3572 participantsIncyte Corporation

View Study Details

NCT06538038Recruiting

Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

The goal of the study is to collect data on patients treated outside of a clinical trial (in routine clinical practice) with standard of care osimertinib with or without chemotherapy in Epidermal Grow...

Palo Alto, CA538 participantsPrECOG, LLC.

View Study Details

NCT05865301Recruiting

Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy

To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozog...

Palo Alto, CA500 participantsStanford University

View Study Details

NCT06973187Recruiting

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

The purpose of this study is to evaluate the efficacy and safety of BGB-16673 alone compared with pirtobrutinib in patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or smal...

Palo Alto, CAPHASE3500 participantsBeOne Medicines

View Study Details

NCT07277231Recruiting

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

The purpose of this study is to investigate the efficacy and safety of fixed-duration sonrotoclax (also known as BGB-11417) plus zanubrutinib (also known as BGB-3111) (SZ) compared with fixed-duration...

Palo Alto, CAPHASE3500 participantsBeOne Medicines

View Study Details

NCT07003919Recruiting

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy....

Palo Alto, CAPHASE3480 participantsDBV Technologies

View Study Details

NCT04065399Recruiting

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Phase 1 dose escalation will determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of revumenib in participants with acute leukemia. In Phase 2, participants will be enrolled...

Palo Alto, CAPHASE1447 participantsSyndax Pharmaceuticals

View Study Details

NCT06859424Recruiting

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

The purpose of this clinical trial is to compare drug combinations to learn which drugs work best to prevent graft-versus-host-disease (GVHD) in people who have received a stem cell transplant. The so...

Palo Alto, CAPHASE2358 participantsCenter for International Blood and Marrow Transplant Research

View Study Details

NCT06588478Recruiting

A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The main purpose of Part 1 of this study is to assess the efficacy and safety of 3 dose levels of Pirtobrutinib in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (S...

Palo Alto, CAPHASE2249 participantsLoxo Oncology, Inc.

View Study Details

NCT03850574Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelod...

Palo Alto, CAPHASE1240 participantsAptose Biosciences Inc.

View Study Details

NCT06137118Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

This is a Phase 1/2, global multicentre, open-label, single-arm, dose escalation and dose optimisation study of AZD0486 to evaluate the safety, tolerability, and efficacy of AZD0486 monotherapy in par...

Palo Alto, CAPHASE1236 participantsAstraZeneca

View Study Details

NCT06501196Recruiting

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk my...

Palo Alto, CAPHASE1170 participantsBlossomHill Therapeutics

View Study Details

NCT06681220Recruiting

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

Randomized phase 2, multicenter, biomarker directed clinical trial with a safety lead-in to assess the efficacy of Stenoparib plus Temozolomide (TMZ) in relapsed Small Cell Lung Cancer patients. Parti...

Palo Alto, CAPHASE1166 participantsVA Office of Research and Development

View Study Details

NCT03898596Recruiting

Umbilical Vessel Catheterization Under ECG Monitoring and Guidance

Umbilical venous catheters (UVC) are typically places with poor guidance and some radiological confirmation. Misplacement of the catheter could lead to its placement in other unintended anatomical are...

Palo Alto, CANA150 participantsStanford University

View Study Details

NCT04142437Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with ...

Palo Alto, CA150 participantsBayer

View Study Details

NCT04402788Recruiting

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

This phase II/III trial compares the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab ...

Palo Alto, CAPHASE2138 participantsNational Cancer Institute (NCI)

View Study Details

NCT07220811Recruiting

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy: This is a Phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating RPT904, a next-generat...

Palo Alto, CAPHASE2100 participantsRAPT Therapeutics, Inc.

View Study Details

NCT05848687Recruiting

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets...

Palo Alto, CAPHASE190 participantsTanja Andrea Gruber

View Study Details

NCT06116682Recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a ...

Palo Alto, CAPHASE288 participantsSWOG Cancer Research Network

View Study Details

NCT04616560Recruiting

Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Newly Diagnosed, Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor

This phase I/II trial studies the effects of trastuzumab deruxtecan (DS-8201a) in treating patients with osteosarcoma, Wilms tumor (WT) or desmoplastic small round cell tumor (DSRCT) that is newly dia...

Palo Alto, CAPHASE155 participantsNational Cancer Institute (NCI)

View Study Details

NCT07070219Recruiting

A Study of CTD402 in T-ALL/LBL Patients

The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients. Participants with relapsed/refractory T-ALL/LBL over the age o...

Palo Alto, CAPHASE154 participantsBIOHENG THERAPEUTICS US LLC

View Study Details

NCT06408194Recruiting

Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies

The primary purpose of this study is to determine safety, feasibility, and the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) of CD22 Chimeric Antigen Receptor T-Cell Therapy (CART) cell...

Palo Alto, CAPHASE128 participantsStanford University

View Study Details

NCT06551584Recruiting

Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT

The study goal is to characterize the safety of the combination of Orca-T with dual agent GVHD prophylaxis....

Palo Alto, CAPHASE124 participantsStanford University

View Study Details

NCT05642455Recruiting

SPEARHEAD-3 Pediatric Study

This is a pediatric basket study to investigate the safety and efficacy of afamitresgene autoleucel in HLA-A\*02 eligible and MAGE-A4 positive subjects aged 2-17 years of age with advanced cancers....

Palo Alto, CAPHASE120 participantsAdaptimmune

View Study Details

NCT06561152Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

To determine the efficacy of the combination of tagraxofusp, cladribine, and cytarabine....

Palo Alto, CAPHASE120 participantsStanford University

View Study Details

NCT07306832Recruiting

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Acute myeloid leukemia (AML) is an aggressive blood cancer, withwith few options for participants who relapse after treatment or who don't respond to treatment. This study will assess the adverse even...

Palo Alto, CAPHASE118 participantsAbbVie

View Study Details

NCT05188170Recruiting

Niclosamide in Pediatric Patients With Relapsed and Refractory AML

Protocol is designed to evaluate a niclosamide dose escalation scale in combination with cytarabine as a therapeutic modality for pediatric subjects with relapsed/refractory acute myeloid leukemia....

Palo Alto, CAPHASE116 participantsStanford University

View Study Details

About Leukemia Clinical Trials in Palo Alto

Leukemia is a group of blood cancers that develop in the bone marrow and result in abnormal white blood cells. Types include acute myeloid (AML), acute lymphoblastic (ALL), chronic myeloid (CML), and chronic lymphocytic (CLL). Treatment varies by type and may include chemotherapy, targeted therapy, and stem cell transplant.

There are currently 33 leukemia clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 17,380 participants. Research is being sponsored by Stanford University, Loxo Oncology, Inc., BeiGene and 19 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Leukemia Clinical Trials in Palo Alto — FAQ

Are there leukemia clinical trials in Palo Alto?

Yes, there are 33 leukemia clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Palo Alto?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.

Are clinical trials in Palo Alto free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.

What leukemia treatments are being tested?

The 33 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for leukemia.

Data updated July 19, 2026 from ClinicalTrials.gov